

**AMENDMENTS TO THE CLAIMS:**

Please amend claims 1-42 as follows:

1. (Original) A solid drug delivery composition comprising one or more NO-donating Non Steroidal Antiinflammatory Compound (s) (NO-donating NSAID (s) ) absorbed into porous particles.
2. (Original) The solid drug delivery composition according to claim 1 wherein one or more NO- donating NSAID(s) in oily form is absorbed into porous particles.
3. (Original) The solid drug delivery composition according to claim 1 wherein one or more NO- donating NSAID(s) in melted form is absorbed into porous particles.
4. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to~~ 3 wherein the porous particles are selected from the group consisting of dibasic calcium phosphate, anhydrous, microcrystalline cellulose and pregelatinised starch or a mixture thereof.
5. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to~~ 4 wherein the porous particles are spherical with a particle size between 50 and 500  $\mu\text{m}$ .
6. (Original) The solid drug delivery composition according to claim 5 wherein the particle size of the spherical porous particles is between 100 and 150  $\mu\text{m}$ .
7. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to~~ 4 wherein the pore size of the porous particles is between 10 and 1000  $\text{\AA}$ .
8. (Original) The solid drug delivery composition according to claim 7 wherein the pore size of the porous particles is between 20 and 750  $\text{\AA}$ .

9. (Original) The solid drug delivery composition according to claim 8 wherein the pore size of the porous particles is between 50 and 500 Å.

10. (Currently Amended) The solid drug delivery composition according to ~~any one of claims 1 to 9~~ wherein one or more NO-donating NSAID(s) is absorbed together with one or more surfactant (s) into the porous particles.

11. (Currently Amended) The solid drug delivery composition according to ~~any one of claims 1 to 9~~ comprising a combinations of

- a) porous particles comprising an NO-donating NSAID and one or more surfactant(s) and
- b) porous particles comprising an NO-donating NSAID without surfactant.

12. (Currently Amended) The solid drug delivery composition according to ~~any one of claims 10 to 11~~ wherein the NO-donating NSAID(s) are the same.

13. (Currently Amended) The solid drug delivery composition according to ~~any one of claims 10 to 12~~ wherein the surfactant (s) is non-ionic.

14. (Original) The solid drug delivery composition according to claim 13 wherein the surfactant(s) is a block co-polymer.

15. (Original) The solid drug delivery composition according to claim 13 wherein the surfactant(s) is a poloxamer.

16. (Original) The solid drug delivery composition according to claim 13 wherein the surfactant(s) is a polyoxyethylene polyoxybutylene block copolymer.

17. (Currently Amended) The solid drug delivery composition according to ~~any one of claims 10 to 16~~ wherein the ratio NO-donating NSAID(s): surfactant(s) is within the range from 1:0.1 to 1:10(w/w).

18. (Original) The solid drug delivery composition according to claim 17 wherein the ratio NO-donating NSAID(s): surfactant(s) is within the range from 1:0.3 to 1:3(w/w).

19. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to 18~~ wherein the NO-donating NSAID is an NO-donating naproxen.

20. (Original) The solid drug delivery composition according to claim 19 wherein the NO-donating naproxen is 4-(nitrooxy)butyl-(S)-2- (9-methoxy-2-naphtyl)-propanoate.

21. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to 18~~ wherein the NO-donating NSAID is an NO-donating diclofenac.

22. (Original) The solid drug delivery composition according to claim 21 wherein the NO-donating diclofenac is 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid 4-(nitrooxy)-butyl ester.

23. (Original) The solid drug delivery composition according to claim 21 wherein the NO-donating diclofenac is 2-[2-(nitrooxy)ethoxy]ethyl {2-[ (2, 6-dichlorophenyl)amino] phenyl} acetate.

24. (Currently Amended) The solid drug delivery-composition according to ~~any one of~~ claims 1 ~~to 18~~ wherein the NO-donating NSAID is an NO-donating ketoprofen.

25. (Original) The solid drug delivery composition according to claim 24 wherein the NO-donating ketoprofen is 2-(3-benzoyl-phenyl)-propionic acid 3-nitrooxy-propyl ester or 2-(3-benzoyl-phenyl)-propionic acid 4-nitrooxymethyl-benzyl ester.

26. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to 25~~ wherein the porous particles comprising an NO-donating NSAID, optionally mixed with one or more surfactant(s), are mixed together with enteric coated pellets comprising a H<sup>+</sup>,K<sup>+</sup>-ATPase inhibitor.

27. (Original) The solid drug delivery composition according to claim 26 wherein the porous particles comprising an NO-donating naproxen, an NO-donating diclofenac, an NO-donating ketoprofen or an NO-donating ketorolac, optionally mixed with one or more surfactant(s), are mixed together with enteric coated pellets comprising omeprazole, esomeprazole, lansoprazole, pantoprazole or rabeprazole, leminoprazole or a pharmaceutical acceptable salt thereof.

28. (Currently Amended) Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to ~~any one of claims 1 to 25~~ comprising mixing the NO-donating NSAID(s), optionally in oily or melted form, with porous particles.

29. (Currently Amended) Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to ~~any one of claims 1 to 25~~ comprising:

- a) dissolving the NO-donating NSAID(s) in one or more alcohol(s),
  - b) adding the porous particles during stirring,
  - c) evaporating the added alcohol(s),
  - d) recovering the porous particles comprising the NO-donating NSAID(s),
- with a) and b) in optional order.

30. (Currently Amended) Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to ~~any one of claims 1 to 25~~ comprising:

- a) melting the NO-donating NSAID(s),
  - b) adding the porous particles,
  - c) stirring the obtained mixture,
  - d) recovering the porous particles comprising the NO-donating NSAID(s),
- with a) and b) in optional order.

31. (Currently Amended) Process for producing porous particles comprising one or more NO-donating NSAID(s) and one or more surfactant(s) according to ~~any one of claims 1 to 25~~ comprising:

- a) mixing the NO-donating NSAID(s) and the surfactant(s),

- b) adding the porous particles,
  - c) stirring the obtained mixture,
  - d) recovering the porous particles comprising the NO-donating NSAID(s) and the surfactant(s),
- with a) and b) in optional order.

32. (Currently Amended) Process for producing the porous particles comprising one or more NO-donating NSAID(s) and one or more surfactant(s) according to ~~any one of~~ claims 1 ~~to~~ 25 comprising :

- a) melting NO-donating NSAID(s) and the surfactant(s),
  - b) adding the porous particles,
  - c) stirring the obtained mixture,
  - d) recovering the porous particles comprising NO-donating NSAID(s) and the surfactant (s),
- with a) and b) in optional order.

33. (Currently Amended) Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to ~~any one of~~ claims 1 ~~to~~ 25 comprising:

- a) mixing the NO-donating NSAID(s) and the porous excipient,
- b) adding water, stepwise, continuously, in one portion,
- c) extruding the obtained mixture into particles,
- d) spheronising the obtained particles,
- e) drying the obtained mixture,
- f) recovering the porous particles comprising the NO-donating NSAID(s).

34. (Original) The process according to claim 33 wherein the NO-donating NSAID(s) in step a) is pre-heated.

35. (Currently Amended) The process according to ~~any one of~~ claims 28 ~~to~~ 34 wherein the NO-donating NSAID(s) are the same.

36. (Currently Amended) ~~The~~A solid drug delivery composition comprising one or more NO-donating Non Steroidal Antiinflammatory Compound (s) (NO-donating NSAID (s) ) absorbed into porous particles ~~the porous particles according to any one of claims 1 to 25~~ wherein the porous particles have been produced according to ~~any one of claims 28 to 35~~, are mixed with pharmaceutically acceptable excipients and compressed into a tablet.

37. (Currently Amended) ~~The~~A solid drug delivery composition comprising one or more NO-donating Non Steroidal Antiinflammatory Compound (s) (NO-donating NSAID (s) ) absorbed into porous particles ~~the porous particles according to any one of claims 1 to 25~~ wherein the porous particles have been produced according to ~~any one of claims 28 to 35~~, are filled into a capsule.

38. (Currently Amended) The solid drug delivery composition according to claims 36 and ~~37~~ wherein the capsules or tablets are coated.

39. (Currently Amended) Use of the solid drug delivery composition according to ~~any one of the claims 1 to 27~~ for the manufacture of a medicament for treating pain.

40. (Currently Amended) Use of the solid drug delivery composition according ~~according to any one of the claims 1 to 27~~ for the manufacture of a medicament for treating inflammation.

41. (Currently Amended) A method for the treatment of pain comprising oral administration to a patient suffering therefrom a solid compound delivery composition according to ~~any one of claims 1 to 27~~.

42. (Currently Amended) A method for the treatment of inflammation comprising oral administration to a patient suffering therefrom a solid compound delivery composition according to ~~any one of claims 1 to 27~~.